BI Asset Management Fondsmaeglerselskab A S Has $16.97 Million Stock Holdings in Bio-Techne Corp $TECH

BI Asset Management Fondsmaeglerselskab A S raised its stake in Bio-Techne Corp (NASDAQ:TECH) by 3.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 305,087 shares of the biotechnology company’s stock after purchasing an additional 10,804 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned 0.20% of Bio-Techne worth $16,972,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Oak Thistle LLC raised its holdings in Bio-Techne by 1.9% in the 3rd quarter. Oak Thistle LLC now owns 9,314 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 173 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Bio-Techne by 5.6% during the third quarter. Exchange Traded Concepts LLC now owns 3,630 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 192 shares during the period. Farther Finance Advisors LLC lifted its holdings in Bio-Techne by 11.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,883 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 198 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in Bio-Techne by 5.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 4,134 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 219 shares during the last quarter. Finally, Arizona State Retirement System boosted its stake in Bio-Techne by 0.5% in the 3rd quarter. Arizona State Retirement System now owns 46,356 shares of the biotechnology company’s stock valued at $2,579,000 after purchasing an additional 220 shares during the period. Institutional investors and hedge funds own 98.95% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company lifted their target price on Bio-Techne from $59.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Benchmark reissued a “buy” rating on shares of Bio-Techne in a report on Tuesday. Deutsche Bank Aktiengesellschaft set a $72.00 target price on shares of Bio-Techne and gave the stock a “buy” rating in a research report on Friday, December 12th. TD Cowen reiterated a “buy” rating and issued a $80.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Thursday. Finally, Stifel Nicolaus set a $65.00 price target on Bio-Techne and gave the stock a “hold” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $72.31.

Bio-Techne Stock Down 4.1%

NASDAQ TECH opened at $65.86 on Friday. The business has a fifty day moving average price of $63.25 and a two-hundred day moving average price of $59.25. The stock has a market capitalization of $10.26 billion, a PE ratio of 129.14, a PEG ratio of 4.74 and a beta of 1.48. Bio-Techne Corp has a fifty-two week low of $46.01 and a fifty-two week high of $77.03. The company has a debt-to-equity ratio of 0.13, a current ratio of 4.54 and a quick ratio of 2.81.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.03. The company had revenue of $295.88 million during the quarter, compared to analysts’ expectations of $290.20 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.Bio-Techne’s revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.42 EPS. Equities analysts expect that Bio-Techne Corp will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 27th. Stockholders of record on Monday, February 16th will be issued a $0.08 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. Bio-Techne’s dividend payout ratio is 65.31%.

Trending Headlines about Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Q2 results beat analysts: adjusted EPS of $0.46 topped estimates and revenue of ~$296M beat consensus; operating margin improved materially (~244 bps). This supports near‑term profitability momentum. Reuters: Bio-Techne beats quarterly estimates
• Positive Sentiment: Company outlook: management signaled mid‑single‑digit underlying growth for fiscal 2026 with margin expansion and “cell therapy normalization” ahead — a constructive forward signal for revenue recovery and margin leverage. MSN: Guidance and outlook
• Positive Sentiment: Dividend declared: Board approved a $0.08 quarterly dividend (payable Feb. 27) — modest but signals capital return discipline. PR Newswire: Dividend announcement
• Positive Sentiment: Analyst moves: Evercore raised its price target from $62 to $68 (in‑line rating), and Citi reiterated a Buy with an $80 target — mixed but includes higher targets that could support upside. Benzinga: Evercore note
• Neutral Sentiment: Conference call / transcripts available — contains management commentary that investors will parse for cadence on cell‑therapy recovery and margin timing. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Industry developments referenced in roundups (new ECM tech, lab M&A) could be relevant longer term but are not immediate drivers of TECH’s stock. BioTechniques: industry bi‑weekly
• Negative Sentiment: Top‑line softness: reported revenue was roughly flat organically and down ~0.4% YoY — investors disappointed by lack of stronger growth despite the beat. PR Newswire: Q2 results release
• Negative Sentiment: Valuation and expectations: TECH trades at a high P/E and elevated PEG, which increases sensitivity to any growth disappointments and may pressure the stock despite margin gains.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.